Evidence comparison

Rapamycin (Sirolimus) vs Fisetin

How they actually compare on the evidence — trial volume, literature, mechanism, and our honest confidence grade. Higher counts reflect research attention, not proof of superiority.

Western · mTOR inhibitor · prescription

Rapamycin (Sirolimus)

雷帕霉素

75Confidence

Extensive human-trial evidence

RCTs: 2,114
Meta: 646
Trials: 2,368

Key active: Rapamycin / sirolimus (mTOR inhibitor)

Gold-standard animal lifespan data; human longevity off-label, early

mTOR inhibition extends lifespan across yeast, worms, flies, and mice more reproducibly than any other intervention; human longevity use is off-label and dosing/safety (the PEARL trial and others) is the open question.

Full Rapamycin (Sirolimus) evidence →

Western · Senolytic · flavonoid

Fisetin

漆黄素

66Confidence

Early / limited human trials

RCTs: 7
Meta: 12
Trials: 36

Key active: Fisetin (flavonoid senolytic)

Strong animal senolytic data; human trials early

Fisetin selectively clears senescent cells and extended lifespan and healthspan in aged mice; human senolytic trials are early-stage, making this promising-but-unproven.

Full Fisetin evidence →

Need this for a decision?

Get a custom dossier comparing your shortlist.

We build evidence-graded comparisons for formulators, brands, clinics, and investors.

Commission research

Informational only — not medical advice or a recommendation to take either. Trial and literature counts are registry/database matches and include endpoints beyond longevity. See each ingredient page for sources.